Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.40 |
| ▸ | POLRMT | O00411 | 1/20 | 0.40 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.39 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129820 | 1.00 | P2RX1 (0.43) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL24699896 | 0.94 | P2RX1 (0.38) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL15682900 | 0.93 | P2RX1 (0.43) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17525235 | 0.93 | P2RX1 (0.43) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL24700004 | 0.91 | P2RX1 (0.41) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17124612 | 0.89 | P2RX1 (0.38) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17129823 | 0.89 | POLRMT (0.47) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17129838 | 0.89 | POLRMT (0.47) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17129837 | 0.89 | P2RX1 (0.42) | P2RX1P2RX3P2RX4P2RX2POLRMT | |
| SCHEMBL17129812 | 0.89 | P2RX1 (0.42) | P2RX1P2RX3P2RX4P2RX2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242988-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, RNGTT, NT5C3B | P2RX1 1369/4885P2RX3 1599/4885P2RX4 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.